We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

214 hedge funds and large institutions have $1.42B invested in TG Therapeutics in 2023 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 61 increasing their positions, 62 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $41.9M | Put options by funds: $21.1M

50% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 36

28% more capital invested

Capital invested by funds: $1.11B → $1.42B (+$315M)

8% more funds holding

Funds holding: 198 → 214 (+16)

0.59% more ownership

Funds ownership: 64.24% → 64.83% (+0.59%)

2% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 62

Holders
214
Holders Change
+16
Holders Change %
+8.08%
% of All Funds
3.41%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
54
Increased
61
Reduced
62
Closed
36
Calls
$41.9M
Puts
$21.1M
Net Calls
+$20.8M
Net Calls Change
-$6.1M

Top Buyers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
+$159M
2
JFG
Jefferies Financial Group
New York
+$77.5M
3
GTC
Ghost Tree Capital
New York
+$16.7M
4
SSA
Schonfeld Strategic Advisors
New York
+$15.2M
5
DCM
Driehaus Capital Management
Illinois
+$12.9M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$54.2M
2
MC
Maverick Capital
Texas
-$51.1M
3
State Street
State Street
Massachusetts
-$42.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$32.3M
5
WP
Woodline Partners
California
-$30.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital Fund Management (CFM)
226
Capital Fund Management (CFM)
France
– -$797K -52,470 Closed
Belvedere Trading
227
Belvedere Trading
Illinois
– -$531K -44,861 Closed
BC
228
Bridgefront Capital
Texas
– -$524K -44,279 Closed
PCM
229
Prelude Capital Management
New York
– -$439K -37,127 Closed
KI
230
Kula Investments
Illinois
– -$342K -28,890 Closed
SCA
231
Sassicaia Capital Advisers
New York
– -$272K -23,000 Closed
BCM
232
Bayesian Capital Management
New York
– -$267K -22,610 Closed
DCM
233
Dupont Capital Management
Delaware
– -$223K -18,889 Closed
Man Group
234
Man Group
United Kingdom
– -$215K -18,200 Closed
Walleye Trading
235
Walleye Trading
New York
– -$274K -18,049 Closed
XT
236
XTX Topco
Cayman Islands
– -$209K -17,695 Closed
GT
237
Glenmede Trust
Pennsylvania
– -$184K -15,562 Closed
AGM
238
Alpine Global Management
New York
– -$137K -11,578 Closed
Amundi
239
Amundi
France
– -$144K -11,009 Closed
CC
240
Corton Capital
Ontario, Canada
– -$127K -10,733 Closed
LP
241
LMR Partners
United Kingdom
– -$118K -10,000 Closed
WI
242
WJ Interests
Texas
– -$35.5K -3,000 Closed
RFG
243
RFP Financial Group
Georgia
– -$11.8K -1,000 Closed
RG
244
Retirement Group
California
– -$8K -700 Closed
AWM
245
Accurate Wealth Management
Florida
– -$8.21K -680 Closed
MCC
246
Money Concepts Capital
Florida
– -$1.47K -124 Closed
FFA
247
Farther Finance Advisors
California
– -$1.12K -95 Closed
BTI
248
Blue Trust Inc
Georgia
– -$532 -35 -36%
FGAM
249
Financial Gravity Asset Management
Texas
– -$10 -12 Closed
C
250
Covestor
United Kingdom
– +$182 +12 New
6 7 8 9
10

TGTX Hedge Fund Activity: Q1 2023 in Review

214 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2023, worth a combined $1.42B — up 28% from $1.11B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new TGTX positions and 36 closed out — a net gain of 18 holders — while 61 added to existing stakes and 62 trimmed.

The largest buyer was Darwin Global Management, opening a new position worth an estimated $159M. The largest seller was Millennium Management, cutting an estimated $54.2M.

  • 214 institutional investors held TG Therapeutics (TGTX) as of Q1 2023, up from 198 in Q4 2022.
  • Funds reported $1.42B of TG Therapeutics stock for Q1 2023, up 28% quarter-over-quarter.
  • 54 funds opened new TG Therapeutics positions in Q1 2023 and 36 closed out, a net change of +18 holders.
  • The largest TG Therapeutics buyer in Q1 2023 was Darwin Global Management, an estimated $159M added.
  • The largest TG Therapeutics seller in Q1 2023 was Millennium Management, an estimated $54.2M sold.

Based on aggregated 13F filings for Q1 2023.